Revolution Medicines, Inc. RVMD
Composite 36/100; the shares have moved about 73% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Quality ranks 4/100 — a strong mark against it.
Momentum ranks 81/100 — a strong point in its favour. Balance-sheet strength ranks 70/100 — a moderate point in its favour.
Quality ranks 4/100 — a strong mark against it. Valuation ranks 6/100 — a strong mark against it.
What the company does Revolution Medicines is a clinical-stage oncology company focused on RAS-addicted cancers, developing RAS(ON) inhibitors and RAS companion inhibitors. Its lead asset, daraxonrasib (RMC-6236), is in mid-stage trials, with zoldonrasib (RMC-9805) in phase 3 for 1L PDAC. The pipeline targets multiple RAS variants (e.g., G12C, G12D, G12V) to disrupt tumor growth.
Key financials ROE -76.7%, ROA -37.5%, and ROCE -68.0% reflect heavy R&D investment with no revenue. Gross/operating/net margins are 0.0%, and revenue growth is -95.2%. Debt/equity is 0.29, with a current ratio of 6.79 and Altman Z-score of 28.70, indicating solvency but high cash burn.
Stock health Momentum is strong: +36.73% (3m), +97.44% (6m), and +419.24% (12m), with RSI(14) at 61.50. Strength and momentum scores are 72.8 and 88.5, respectively, but quality (7.4) and growth (34.8) lag.
Price vs fair value The stock trades at a **discount of 7.72%** versus the 12-month target of 207.00 (analyst count: 21). - Shares surged after a Motley Fool headline (2026-07-29) touted its outperformance vs. Lilly, J&J, and AbbVie. - Analysts cite potential in daraxonrasib’s monotherapy data and combo trials (e.g., RMC-6236 + RMC-9805). - High momentum (419.24% YoY) may justify premium despite weak fundamentals (ROE -76.7%).
Looking forward Key catalysts include phase 3 PDAC combo trial results and updates on G12V/G13C programs. Execution risk remains high given early-stage pipeline and negative profitability metrics. Valuation hinges on clinical success and RAS-targeting leadership.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.